Berardino Pollio

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. Supporting Information Filename Description jcmm71216-sup-0001-Supinfo.docxWord 2007 document , 5.3 MB Table S1: Study population characteristics. Table S2: Flow cytometry antibodies. Table S3: List of oligonucleotides used as Forward and Reverse for Real-Time qPCR.

Introduction Managing pregnancy in carriers/women with haemophilia involves four key objectives: preconception and prenatal care, minimizing maternal bleeding, choosing the delivery mode to reduce foetal/neonatal bleeding, and postpartum care. The optimal factor VIII/IX level at delivery and the best delivery method to mitigate maternal and foetal complications are still debated. Aim To share real-world clinical management in Italian haemophilia treatment centres.

CONFLICT OF INTEREST STATEMENT EB reports acting as consultant for Sobi, Pfizer, Bayer and Takeda. AC reports acting as consultant and/or member of the advisory board and/or speaker for Bayer, BioMarin, Novo Nordisk, Sobi, Takeda and Werfen. PAC reports receiving speaking honoraria from Pfizer, Roche and Novartis. RG reports acting as a consultant in advisory boards for Bayer, BioMarin, CSL Behring, Novo Nordisk, Pfizer, Roche, Sobi and Takeda.